Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature
- PMID: 12858457
Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature
Abstract
Objective: To study the clinical course, response to therapy, and longterm outcome of pure sensory neuropathy (PSN) in a series of patients with primary Sjögren's syndrome (SS) followed prospectively in our referral centers.
Methods: We studied 15 patients (13 women, 2 men) with primary SS and PSN. All patients fulfilled 4 or more of the European diagnostic criteria.
Results: At diagnosis of PSN, clinical manifestations included numbness and paresthesias (11 patients), trigeminal neuropathy (6 patients), and Adie's pupil syndrome (4 patients). In 7 patients, PSN was diagnosed prior to SS, in 5 the diagnoses were made simultaneously, and in the remaining 3 patients PSN was diagnosed after the appearance of SS symptomatology. The mean duration of the prospective PSN followup was 10 years (range 1-20). The progression of PSN was acute in 1 patient (producing severe dysfunction in less than 1 month), subacute in 3 patients, and in the remaining 11, the symptoms progressed slowly over the ensuing years to other extremities. Patients were treated with corticosteroids (n = 13), cyclophosphamide (n = 4), and intravenous immunoglobulins (n = 1), and 2 patients received no treatment. In spite of treatment, most patients showed an indolent and insidious longterm PSN course.
Conclusion: We found 3 differentiated clinical courses of the PSN in patients with primary SS: subacute progression in less than 1 month (7%), late acceleration of PSN 2-4 years after an initial indolent onset (20%), and a very longterm insidious, chronic evolution (73%). Prospective analysis of the longterm course of PSN shows a chronic and insidious evolution in most patients with PSN and SS, with a poor response to treatment, although stabilization of symptomatology for long periods is often observed.
Similar articles
-
Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: a national multicentric retrospective study.Arthritis Care Res (Hoboken). 2011 Sep;63(9):1339-44. doi: 10.1002/acr.20495. Arthritis Care Res (Hoboken). 2011. PMID: 21584943
-
Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids.J Rheumatol. 2006 Apr;33(4):709-11. J Rheumatol. 2006. PMID: 16583474
-
Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy.Arthritis Rheum. 2007 Dec 15;57(8):1520-9. doi: 10.1002/art.23102. Arthritis Rheum. 2007. PMID: 18050172
-
Invited review: peripheral neuropathy in Sjogren's syndrome.Muscle Nerve. 1990 Jul;13(7):570-9. doi: 10.1002/mus.880130703. Muscle Nerve. 1990. PMID: 2167450 Review.
-
[3 cases of rare peripheral neuropathies associated with primary Gougerot-Sjögren syndrome].Rev Neurol (Paris). 1993;149(8-9):481-4. Rev Neurol (Paris). 1993. PMID: 8009146 Review. French.
Cited by
-
Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren's syndrome.J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):967-9. doi: 10.1136/jnnp.2005.084533. J Neurol Neurosurg Psychiatry. 2006. PMID: 16844955 Free PMC article.
-
Neurologic Complications Associated with Sjögren's Disease: Case Reports and Modern Pathogenic Dilemma.Case Rep Neurol Med. 2014;2014:590292. doi: 10.1155/2014/590292. Epub 2014 Aug 5. Case Rep Neurol Med. 2014. PMID: 25161786 Free PMC article.
-
Comparative Analysis of Hematological and Immunological Parameters in Patients with Primary Sjögren's Syndrome and Peripheral Neuropathy.J Clin Med. 2023 May 25;12(11):3672. doi: 10.3390/jcm12113672. J Clin Med. 2023. PMID: 37297866 Free PMC article.
-
Recommendations on neurologic, cognitive, and psychiatric manifestations in patients with Sjögren's disease by the Brazilian Society of Rheumatology.Adv Rheumatol. 2025 Feb 11;65(1):7. doi: 10.1186/s42358-025-00438-7. Adv Rheumatol. 2025. PMID: 39934881
-
Treating Sjögren's Syndrome: Insights for the Clinician.Ther Adv Musculoskelet Dis. 2010 Jun;2(3):155-66. doi: 10.1177/1759720X10363246. Ther Adv Musculoskelet Dis. 2010. PMID: 22870445 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical